Director Healy Buys $20.4M of Rapport Stock at $21.00 Offering Price
RAPP is trading near its 52-week low of $22.061 (11% above the low).
Summary
Director James Healy bought 969,480 shares at $21.00 for $20.4M on 2026-10-28, the same price as Rapport's just-closed equity offering. The purchase is a sharp reversal from the recent insider selling trend.
Key Events · Ownership and Investor Activity · RAPP
-
Director Buys $20.4M at Offering Price
James Healy acquired 969,480 shares at $21.00 on 2026-10-28 across four Sofinnova/SummitTX entities, a $20,359,080 open-market purchase.
-
Purchase Follows Priced $355M Raise
The $21.00 price matches the equity component of the capital raise priced 2026-10-28 ($175M of stock at $21.00 plus $150M of 2.25% convertible notes), so the buy was struck at the deal price, not today's $24.56.
-
Reverses Recent Insider Selling
Over the prior 90 days insiders were net sellers of about $4.9M; this single purchase is roughly four times that amount.
-
Holdings Rise to 2.8M Shares
Post-transaction reported ownership is 2,815,707 shares, held indirectly through Sofinnova Venture Partners XI and SummitTX vehicles.
Analysis · RAPP · Life Sciences
A director put $20.4 million of real money into the stock at $21.00 — the exact price of the just-closed capital raise — rather than buying in the open market at today's $24.56. That is a large, deliberate commitment from a board member with a front-row view of the RAP-219 Phase 2 win that sent shares higher on 2026-10-20. It also runs against the 90-day insider pattern, which has been net distribution of roughly $4.9M; this single purchase dwarfs that. Because the shares sit in Sofinnova and SummitTX funds Healy manages, the buy reflects the fund complex's conviction rather than a personal account, and it lifts his reported holdings to 2,815,707 shares.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 891 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RAPP was trading at $24.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $22.06 to $52.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.